- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Interventions
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Drug · Other
- Lead sponsor
- OPKO IP Holdings II, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Bannockburn, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 147
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
- Interventions
- Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol, Paricalcitol Oral Capsule
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism
- Interventions
- Cinacalcet HCl, Standard of Care
- Drug · Dietary Supplement
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more
- Conditions
- CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
- Interventions
- CTAP101
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
- Conditions
- Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
- Interventions
- miRNAseq analysis, Standard treatment for bone disorder
- Procedure · Drug
- Lead sponsor
- Thomas Nickolas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Osteopenia, Renal Osteodystrophy
- Interventions
- pamidronate
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hyperparathyroidism, Secondary, Kidney Failure, Chronic
- Interventions
- DP001 softgel capsules, Placebo
- Drug
- Lead sponsor
- Deltanoid Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 11 more
- Conditions
- Primary Hyperparathyroidism, Parathyroid Cancer, Multiple Endocrine Neoplasias, Heritable Hyperparathyroidism, Hyperparathyroid-jaw Tumor Syndrome
- Interventions
- 18F-FCH, NeuroEXPLORER
- Drug · Device
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parathyroid Tumor, Primary Hyperparathyroidism, Secondary Hyperparathyroidism (SHPT), Tertiary Hyperparathyroidism
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 839 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2032
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Phosphorus and Calcium Disorders, Chronic Kidney Disease Mineral and Bone Disorder, Chronic Kidney Diseases
- Interventions
- High Phosphorus Diet, Low Phosphorus Diet
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Chronic-kidney Disease Stage 5D on Stable Hemodialysis
- Interventions
- Single VS-105/placebo to healthy, Multiple VS-105/placebo to healthy, Multiple VS-105/placebo to HD subjects
- Drug
- Lead sponsor
- Vidasym, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lakewood, Colorado
- Conditions
- Chronic Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- Saint Louis VA Medical Center
- Federal
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hyperparathyroidism
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Vitamin D Deficiency, Secondary Hyperparathyroidism, Obesity
- Interventions
- Ergocalciferol, Cholecalciferol
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Osteoporosis, Bone Diseases, Endocrine, Hyperparathyroidism
- Interventions
- Parathyroid Hormone (1-34)
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 24 Years to 35 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hyperparathyroidism, Primary
- Interventions
- Scheduling Navigation, Without Scheduling Navigation
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary
- Interventions
- Cinacalcet hydrochloride, Standard of Care
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 28 Days to 2189 Days
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Sevelamer Carbonate, Placebo
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Primary Hyperparathyroidism
- Interventions
- eplerenone, amiloride, Placebo, Cinacalcet
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 49
- States / cities
- Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
- Conditions
- Secondary Hyperparathyroidism, End Stage Kidney Disease
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 50
- States / cities
- Anaheim, California • Chula Vista, California • Escondido, California + 43 more
- Conditions
- Secondary Hyperparathyroidism, Hypocalcemia
- Interventions
- Calcitriol
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Calcinosis, Arteriosclerosis, Hyperparathyroidism, Secondary
- Interventions
- calcium acetate, sevelamer, atorvastatin
- Drug
- Lead sponsor
- Nabi Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hyperparathyroidism, Parathyroid, Mobility
- Interventions
- Not listed
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 60 Years to 100 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida